TBPMF News and Press, Tetra Bio-Pharma Inc From 04/30/19

OTTAWA, April 30, 2019 (GLOBE NEWSWIRE) -- Tetra Natural Health, a subsidiary of Tetra Bio-Pharma (TSX VENTURE: TBP) (OTCQB: TBPMF), announces the arrival of twenty (20) containers, or more than 1.7 million cans, of its Hemp Energy Drink in Canada, the first 100% natural energy drink m...

OTTAWA, April 29, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“ Tetra ” or “ TBP ”), (TSX VENTURE: TBP) (OTCQB: TBPMF), and Altus Formulation Inc. (“ Altus ”) today announced the signing of a Joint Venture Agreement under which the two co...

OTTAWA, April 18, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (" Tetra " or the  "Company" ) (TSX-V: TBP) (OTCQB: TBPMF), is pleased to announce that, at a special meeting of shareholders held today (the " Meeting "), the shareholders of the Company voted in favor of an ordinary res...

OTTAWA, April 11, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (" Tetra " or the " Company ") (TSX-V: TBP) (OTCQB: TBPMF), today announced that it has entered into a collaboration agreement with Ovensa Inc. ("Ovensa") to evaluate TRIOZAN™, a proprietary nanomedicine platform f...

Tetra Bio-Pharma ( OTCQB:TBPMF ) is ready to resume its Phase 3 clinical program in advanced cancer pain patients with the objective to assess Health- Related Quality of Life (HrQoL). More news on: Tetra Bio-Pharma Inc., Healthcare stocks news, Read more ...

OTTAWA, April 09, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (" Tetra " or the " Company ") (TSX-V: TBP) (OTCQB: TBPMF), today announced it is ready to resume its Phase 3 clinical program in advanced cancer pain patients with the objective to assess Health- Related Quality of Life ...

OTTAWA, April 01, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (" Tetra " or the " Company ") (TSX-V: TBP) (OTCQB: TBPMF), today announced that the Company has renewed its CEO Guy Chamberland’s employment agreement. “We are extremely pleased with the progress that Gu...

Tetra Bio-Pharma ( OTCQB:TBPMF ) is ready to submit its PPP001 cannabinoid-derived drug as a herbal medicinal product to the European Medicines Agency. More news on: Tetra Bio-Pharma Inc., Healthcare stocks news, Read more ...

OTTAWA, March 27, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (" Tetra " or the " Company ") (TSX-V: TBP) (OTCQB: TBPMF) , today announced it is ready to submit its PPP001 cannabinoid-derived drug as a herbal medicinal product to the European Medicines Agency. The pre-marketi...

Thanks to the emergence of the marijuana investing space, new plays are being brought to the market for public capital to support. As such, some marijuana companies have turned to the medical sector as a source of inspiration to find the benefits of the cannabis plant against various disease...